{"id":"NCT02355886","sponsor":"University of Washington","briefTitle":"Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy","officialTitle":"Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-04-22","primaryCompletion":"2018-02-28","completion":"2019-02-28","firstPosted":"2015-02-04","resultsPosted":"2019-06-04","lastUpdate":"2019-06-04"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Bladder Carcinoma"],"interventions":[{"type":"DRUG","name":"Gabapentin","otherNames":["Gralise","Neurontin"]},{"type":"OTHER","name":"Placebo","otherNames":["placebo therapy","PLCB","sham therapy"]},{"type":"OTHER","name":"Questionnaire Administration","otherNames":[]}],"arms":[{"label":"Arm I (gabapentin)","type":"EXPERIMENTAL"},{"label":"Arm II (placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs. Gabapentin may reduce the amount of pain medicine required after surgery, improve pain after surgery, and/or reduce the length of hospital stay after surgery.","primaryOutcome":{"measure":"Patient Total Equivalent Analgesic Requirement (Morphine Equivalents)","timeFrame":"48 hours post-radical cystectomy","effectByArm":[{"arm":"Arm I (Gabapentin)","deltaMin":297.65,"sd":179.95},{"arm":"Arm II (Placebo)","deltaMin":396.16,"sd":149.84}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["nausea","sedation"]}}